21:48 , Dec 2, 2016 |  BC Week In Review  |  Company News

Tokushima University, Shionogi deal

The university granted Shionogi exclusive, worldwide rights to develop A2NTX, a low molecular weight botulinum neurotoxin type A2 that is being developed to treat post-stroke spasticity of the upper and lower limbs. The partners declined...